Page 1
Effects of renal sympathetic denervation on Effects of renal sympathetic denervation on noradrenaline spillover and systemic blood pressure
in patients with resistant hypertension
Markus Schlaich
Neurovascular Hypertension & Kidney Disease Laboratory
Alfred & Baker Hypertension Network
Melbourne, Australia
Page 2
• This study was sponsored by ARDIAN Inc., Palo Alto, CA, USA.
• The presenter declares to have received consulting fees from ARDIAN Inc. and lecture fees from pharmaceutical companies (Solvay, Servier,
AstraZeneca, Novartis).
Disclosures
Page 2: Baker IDI
AstraZeneca, Novartis).
Page 3
Sympathetic Nervous System Activation -A major Player in CV disease
Page 3: Baker IDI
Page 4
}
nNOS↓↓↓↓
Integration
Cause Central Integration Consequence
Growth↑↑↑↑ (LVH)Arrhythmias
IschemiaHeart Failure
Page 4: Baker IDI
Renal ischemia
Adenosine ↑↑↑↑
NO↓↓↓↓
RAAS↑↑↑↑}
Contributing factors:Obesity
LeptinSmoking
Hypercapnia
HypercholesterolemiaOxidative stress
InflammationEndothelial factors
Growth↑↑↑↑
Vasoconstriction
Atherosclerosis
Arterial compliance ↓↓↓↓
Sodium retentionHypervolemia
RAAS↑↑↑↑
Proteinuria
Glomerulosclerosis
Aggravation of hypertension
BP↑↑↑↑↑↑↑↑
Page 6
Selective Renal Denervation
Electrode
Insulated Arch Wire
Page 6: Baker IDI
• Disrupt sympathetic nerve traffic to and from the kidneys
• Disable the renal nerves via RF ablation
• A 40-minute catheter-based procedure
Insulated Arch Wire
Symplicity® Catheter System,
Ardian, Inc., Palo Alto, CA, USA
Page 7
The Renal Nerves
Lumen
Endothelium
Media
Adventitia
Nerves
Lumen
Endothelium
Media
Adventitia
Nerves
Page 7: Baker IDI7
…follow the renal artery to
the kidney
…primarily within the
adventitia
Fat
3 mm
Fat
3 mm3 mm
Page 8
Treatment by Renal RF Catheter
Page 8: Baker IDI
Page 9
Selective Renal Denervation:
Symplicity® Catheter System, Ardian, Inc., Palo Alto, CA, USA
Renal Artery
Page 9: Baker IDI
Focal ablations
spaced along vessel
Multiple focal ablations
↑ circumferential coverage
Aorta
Kidney
Treatments
Page 10
Patients Undergoing Procedure
(N=45)
Patients Anatomically Ineligible for Procedure
(N=5)
Age (years) 58 ± 9 51 ± 8
Gender (% female) 44 20
Baseline Patient Characteristics
Page 10: Baker IDI
Gender (% female) 44 20
Race (% non-Caucasian) 4 0
Diabetes Mellitus II (%) 31 40
CAD (%) 22 20
Heart Rate (bpm) 72 ± 11 79 ± 9
eGFR (mL/min/1.73m2) 81 ± 23 95 ± 15
BP (mmHg) 177/101 ± 20/15 173/98 ± 8/9
Page 11
Patients Undergoing Procedure
(N=45)
Patients Anatomically Ineligible for Procedure
(N=5)
Baseline Patient Characteristics
Page 11: Baker IDI
Number of anti-HTN meds (mean) 4.7 ± 1.5 4.6 ± 0.5
ACE/ARB (%) 96 80
Beta-blocker (%) 76 100
Calcium channel blocker (%) 69 100
Vasodilator (%) 18 0
Diuretic (%) 96 60
Page 12
Office BP: All Treated Patients
Page 12: Baker IDIn=45
Page 13
Evidence for denervation
∆∆∆∆ Renal NE Spillover (n=10)
∆∆∆∆ Total Kidney NE Content (pigs n=70)
Page 13: Baker IDI
-47%
-85%
Page 14
Mean office blood pressure
161/107 141/90
10
20
30
40
50
60
70
80
90
100
Ren
al N
ore
pin
eph
rin
e
Sp
illo
ver
(n
g/m
in)
Left
Kidney
Right
Kidney
Effects of renal denervation on renal and total body NE spillover
Page 14: Baker IDI
0
10
Baseline 30 days after bilateral
denervation
0
100
200
300
400
500
600
700
800
Baseline 30 days after bilateral
denervation
To
tla
Bo
dy
No
rep
inep
hri
ne
Sp
illo
ver
(n
g/m
in)
Page 15
150
200
Baseline 12 months FU1 month FU
ECG
BP
Effects of renal denervation on MSNA
Page 15: Baker IDI
50
100
10 sec
BP
MSNA
56 bursts/min 41 bursts/min 19 bursts/min
Page 16
Conclusions
Selective renal sympathetic denervation via a catheter based
approach using RF ablation
• appears to be a safe procedure
• effectively reduces efferent sympathetic nerve activity (NA spillover )
Page 16: Baker IDI
• appears to inhibit afferent signaling via renal sensory nerves (MSNA )
• is associated with a substantial and sustained reduction in blood pressure
• may represent a treatment option for other conditions characterized by
heightened sympathetic drive
Page 17
Acknowledgements
Alfred Hospital, Melbourne, AU: Cardiology Team
Prof Murray Esler
Dr Tony Walton
Prof Henry Krum
St Vincent’s Hospital, Melbourne, AU: Cardiology Team
A/Prof Rob Whitbourn
John Hunter Hospital, Newcastle, AU: Cardiology Team
Dr Suku Thambar
Page 17: Baker IDI
Dr Suku Thambar
Cardiovascular Center Frankfurt, Germany: Cardiology Team
Prof Horst Sievert
Jagiellonian University, Krakau, Poland: Cardiology Team
Prof Jerzy Sadowski
Dr Krzysztof Bartus
Dr Boguslav Kapelak
Ohio State University, Columbus, Ohio, USA: Prof William Abraham
Prof Paul Sobotka
ARDIAN Inc., Palo Alto, CA, USA
Page 18
Other interesting aspects and open questions
• Predictors of response (age, sex, PMHx, BP, HR, GFR…?)
( 6 patients had BP reduction <10mmHg = non-responders)
• Dipping pattern in
responders (n=12)
67 67
Page 18: Baker IDI
• Glucose control and insulin sensitivity
• Long term effects (re-innervation?...)
• Relevance in other patients cohorts (CHF, CRF, ESRD….)?
33 33